Atrial Fibrillation, or Afib, is the most common type of heart arrhythmia and the number of people diagnosed with AFib is increasing both in the United States and globally.

Saint Luke’s Mid America Heart Institute cardiologists were the first in Kansas and Missouri to participate in a clinical trial for a novel treatment of AFib known as "pulse field ablation."

Dr. Sanjaya Gupta spoke to KSHB about this groundbreaking treatment, as well as the second Saint Luke's patient to undergo pulse field ablation.

Watch the full KSHB story: Saint Luke’s Helps Lead Groundbreaking Clinical Trial for Afib Treatment.